Cart
sales@molnova.com
AZD-9291 mesylate
CAS No. 1421373-66-1
AZD-9291 mesylate ( Osimertinib mesylate;Mereletinib mesylate;AZD9291 mesylate;AZD 9291 mesylate )
Catalog No. M11763 CAS No. 1421373-66-1
A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 50 | In Stock |
|
| 50MG | 72 | In Stock |
|
| 100MG | 87 | In Stock |
|
| 200MG | 104 | In Stock |
|
| 500MG | 120 | In Stock |
|
| 1G | 140 | In Stock |
|
Biological Information
-
Product NameAZD-9291 mesylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.
-
DescriptionA potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively; weak activity against wt EGFR (IC50=184 nM); inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro; exhibits tumor regression in EGFR-mutant tumor xenograft and transgenic models; orally active.Lung Cancer Approved
-
SynonymsOsimertinib mesylate;Mereletinib mesylate;AZD9291 mesylate;AZD 9291 mesylate
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR(L858R);EGFR(L858R/T790M);EGFRL858R/T790M;EGFRL858R
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number1421373-66-1
-
Formula Weight595.71
-
Molecular FormulaC29H37N7O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO
-
SMILESCN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O
-
Chemical Name2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Finlay MR, et al. J Med Chem. 2014 Oct 23;57(20):8249-67.
2. Cross DA, et al. Cancer Discov. 2014 Sep;4(9):1046-61.
3. Eberlein CA, et al. Cancer Res. 2015 Jun 15;75(12):2489-500.
2. Cross DA, et al. Cancer Discov. 2014 Sep;4(9):1046-61.
3. Eberlein CA, et al. Cancer Res. 2015 Jun 15;75(12):2489-500.
molnova catalog
related products
-
Afatinib
Afatinib is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.
-
CO-1686
A potent, highly selective, irreversible inhibitor of mutant EGFR with Ki of 21.5 nM for EGFR L858R/T790M.
-
PF-06747775
A potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.
